PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.45%
Negative revenue growth while 3088.T stands at 1.38%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-3.98%
Negative gross profit growth while 3088.T is at 0.58%. Joel Greenblatt would examine cost competitiveness or demand decline.
-17.81%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-20.34%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-18.30%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-18.29%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-18.29%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.35%
10Y revenue/share CAGR under 50% of 3088.T's 16.71%. Michael Burry would suspect a lasting competitive disadvantage.
4.35%
5Y revenue/share CAGR under 50% of 3088.T's 16.71%. Michael Burry would suspect a significant competitive gap or product weakness.
-22.63%
Negative 3Y CAGR while 3088.T stands at 9.94%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
84.25%
Net income/share CAGR 1.25-1.5x 3088.T's 69.23%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
84.25%
5Y net income/share CAGR 1.25-1.5x 3088.T's 69.23%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
3.41%
Below 50% of 3088.T's 14.64%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
37.80%
Equity/share CAGR of 37.80% while 3088.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
37.80%
Equity/share CAGR of 37.80% while 3088.T is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-6.14%
Negative 3Y equity/share growth while 3088.T is at 38.89%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.53%
Firm’s AR is declining while 3088.T shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
11.89%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
6.36%
Asset growth above 1.5x 3088.T's 2.67%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.37%
BV/share growth above 1.5x 3088.T's 3.55%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
307.59%
We have some new debt while 3088.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
2.63%
SG&A growth well above 3088.T's 3.68%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.